[go: up one dir, main page]

EP2566581A1 - Composition destinée à une utilisation topique dans le cas de maladies rhumatismales - Google Patents

Composition destinée à une utilisation topique dans le cas de maladies rhumatismales

Info

Publication number
EP2566581A1
EP2566581A1 EP11719233A EP11719233A EP2566581A1 EP 2566581 A1 EP2566581 A1 EP 2566581A1 EP 11719233 A EP11719233 A EP 11719233A EP 11719233 A EP11719233 A EP 11719233A EP 2566581 A1 EP2566581 A1 EP 2566581A1
Authority
EP
European Patent Office
Prior art keywords
extracts
preparation
tinctures
fresh
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11719233A
Other languages
German (de)
English (en)
Inventor
Reiner Rittinghausen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2566581A1 publication Critical patent/EP2566581A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a preparation for topical use, in particular in rheumatic diseases. Further, the preparation is useful in blunt sports injuries.
  • rheumatic diseases vary according to the affected organ system.For example, leads the epidemiologically significant inflammatory disease Rheumatoid arthritis, rheumatic arthritis, inflammation and deformity of the joints, especially of the small finger and toe joints, but rheumatic diseases do not only affect the joints, connective tissue, tendons and ligaments are also affected. The causes of rheumatic diseases are not yet finally clarified.
  • Antiphlogistics such as salicylic acid and glucocorticoids application. Among the most important in the
  • Rheumatoid therapy used glucocorticoids include cortisone, cortisol, prednisone, prednisolone and RD 40995 / SAM: AL Dexamethasone.
  • the infections which frequently occur in glucocorticoid therapy represent a further significant disadvantage, in particular in long-term therapy.
  • analgesics such as paracetamol or acetylsalicylic acid are used in the treatment of rheumatic diseases, the disadvantage of which is, for example, that they show a liver-damaging effect, in particular in the case of longer-term use.
  • Other common complaints of the joints and musculoskeletal system are
  • the object of the present invention to provide a means which overcomes at least one of the aforementioned disadvantages of the prior art.
  • the object is achieved by a preparation for topical use, in particular in the case of rheumatic diseases, the preparation comprising, as active ingredients, the following extracts, tinctures, essential oils and / or extracts:
  • Tinctures essential oils and / or extracts of fresh or dried plants or parts of plants of rosemary (Rosmarinus officinalis) or their dry residue, wherein the contents of the respective components are chosen so that the total content of rosemary (Rosmarinus officinalis) or their dry residue, wherein the contents of the respective components are chosen so that the total content of rosemary (Rosmarinus officinalis) or their dry residue, wherein the contents of the respective components are chosen so that the total content of
  • Components does not exceed 100%.
  • Percentage data are in% by volume or% by weight, based on the total volume or total weight of the preparation.
  • Total volume or total weight of the components does not exceed 100 vol .-% or 100 wt .-%.
  • total content refers accordingly to the total volume or total weight of the preparation.
  • rheumatic diseases in the context of the present invention, the various inflammatory diseases of the connective and supporting tissue, especially the
  • the term “dry residue” is understood to mean the dry residue of extracts, tinctures and / or extracts which remains after removal of the extractant.
  • the dry residue may contain a residual amount of extractant, for example water, which may be, for example, in the range from> 1% by weight to ⁇ 30% by weight, preferably in the range from> 1% by weight to ⁇ 5% by weight, based on the total weight of the dry residue.
  • the dry residue can therefore also be present in viscous form.
  • the dry residue is preferably a native dry residue from the extracts, tinctures and / or extracts without additives.
  • the term “dry extract” is understood to mean the dry residue of an extract. Under an "ethanolic dry extract” in the context of this invention, the dry residue of an extract after deduction of the ethanolic
  • tincture is understood to mean excerpted extracts and excerpts from fresh or dried plant parts or whole fresh or dried plants which are produced using alcohols, in particular ethanol, water or ethanol.
  • tincture for the purposes of the present invention also includes so-called “mother tinctures” and mixtures of vegetable press juices with alcohols, water and / or their mixture and / or herbal extracts.
  • tincture drug extracts according to the Homeopathic Pharmacopoeia (HAB), German Pharmacopoeia (DAB) or European Pharmacopoeia (Ph. Eur.) And other European or American pharmacopoeia from fresh or dried plants and / or parts of plants, especially fresh plants and / or plant parts.
  • extract means concentrated, optionally adjusted to a certain active substance content, extracts from fresh or dried plants and / or plant parts of liquid, viscous or dry nature, which are obtained, for example, using alcohols, in particular ethanol , Understood. Extracts can be solid, liquid, oily or viscous.
  • extract for the purposes of this invention, in addition to liquid extracts viscous so-called spissum or thick extracts and dry or Siccum extracts.
  • extract for the purposes of this invention also purified extracts or extract fractions understood. Extracts from plants or parts of plants with essential oils can also be prepared in such a way that the essential oils are removed from the plants or plant parts prior to extraction and this is added again after extraction to the respective extract.
  • the extractants for extracts may also be lipophilic in nature, for example carbon dioxide, and enrich lipophilic components, for example essential oil components in the extract.
  • essential oil is understood to mean extracts soluble in organic solvents or the organic phase of steam distillates from fresh or dried plants or parts of plants which usually have one for the
  • Essential oils are also understood to mean the components of a plant or a plant part which are volatile with water vapor. Extracts, tinctures, essential oils and extracts can be obtained from fresh or dried plants or parts of plants. Plant parts may be aboveground or subterranean parts, for example flowers, leaves or the root, depending on the respectively preferably usable parts of the respective plant.
  • the term "arnica” in the context of this invention comprises plants and / or plant parts of Arnica montana.
  • the term “comfrey” in the context of this invention comprises plants and / or plant parts of Symphytum officinale.
  • the term "rosemary” in the context of this invention comprises plants and / or plant parts of Rosmarinus officinalis.
  • homeopathic tinctures and extracts in particular liquid alcoholic-aqueous plant extracts, or dry and spissum extracts with alcohol-water mixtures are used as extractants or essential oils.
  • ethanol is preferred as the alcohol.
  • a preparation according to the invention containing excipients, tinctures, essential oils and / or extracts of arnica (Arnica montana) in the range of> 2% to ⁇ 40%, extracts, tinctures and / or extracts of comfrey (Symphytum officinale) in the range of> 1.5% to ⁇ 40%, and extracts, tinctures, essential oils and / or extracts of rosemary (Rosmarinus officinalis) in the range of> 0.5% to ⁇ 20%, based on the Total content of the preparation, or whose dry residue comprises, an improved effect in the treatment of muscle and joint pain, rheumatic diseases, especially the symptomatic treatment of rheu
  • blunt trauma such as sprains, bruises, strains,
  • Comfrey's (Symphytum officinale) plant parts and extracts, tinctures, essential oils and / or extracts of fresh or dried plants and / or plant parts of arnica (Arnica montana) and rosemary (Rosmarinus officinalis) can be achieved, so that can be dispensed with a variety of components. This is particularly advantageous because active ingredients
  • the preparation comprises only extracts, tinctures and / or extracts of fresh or dried plants and / or plant parts of comfrey (Symphytum officinale) and extracts, tinctures, essential oils and / or extracts of fresh or dried plants and / or plant parts of Arnica (Arnica montana) and rosemary (Rosmarinus officinalis) as active ingredients.
  • a significant advantage of the preparation is realized by the preparation comprising extracts, tinctures and / or extracts of fresh or dried plants and / or
  • Vegetable parts of comfrey (Symphytum officinale) and extracts, tinctures, essential oils and / or extracts of fresh or dried plants and / or plant parts of arnica (Arnica montana) and rosemary (Rosmarinus officinalis) due to the small number of extracts, tinctures, essential oils and / or extracts of medicinal plants cause no allergic reactions or hypersensitivity reactions, as is often the case with known agents. Therefore, it is particularly useful for long-term use in rheumatic diseases.
  • composition comprising extracts, tinctures and / or extracts of fresh or dried plants and / or
  • Comfrey Symphytum officinale
  • An increasing number of people suffer from allergies or hypersensitivity to ingredients of one or more plants.
  • compositions occur. It is therefore of great advantage that the inventive
  • the preparation may further be distinguished by the fact that it does not cause skin redness and rashes.
  • this has no extracts, tinctures, essential oils and / or extracts of plants, which can cause skin redness and rashes when applied externally, such as monkshood.
  • the preparation according to the invention is distinguished from known plant-based agents in that the preparation contains a special dosage of extracts, tinctures, and / or extracts of comfrey (Symphytum officinale) and extracts, tinctures, essential oils and / or extracts of arnica ( Arnica montana) and rosemary (Rosmarinus officinalis) as active ingredients.
  • the lower limit for good effectiveness is a minimum of 2%, based on the
  • Indicated percentages are preferably based on a liquid extract.
  • a liquid extract With respect to rosemary, the percentages given refer to the essential oil unless otherwise specified. If a liquid extract is concentrated, the volume or the percentage can be correspondingly lower. If a dry extract is used, this has the appropriate amount of ingredients, but advantageously a smaller volume or a smaller percentage than the liquid extract from which
  • Dry extract was obtained, for example, by evaporation.
  • Extracts, tinctures and / or extracts of fresh or dried plants or comfrey plant parts are preferably obtained from the roots or subterranean plant parts.
  • Comfrey contains pyrrolizidine alkaloids, which are widely distributed in higher plants.
  • Pyrrolizidine alkaloids are rapidly absorbed after peroral uptake, but metabolized by metabolism in the liver to toxic pyrrole derivatives. Pyrrolizidine alkaloids can be separated by methods known to those skilled in the art.
  • comer-shaft extracts which have a markedly reduced content of pyrrolizidine alkaloids.
  • pyrrolizidine alkaloid-depleted extracts of comfrey are useful.
  • a significantly reduced content of Pyrrolizidinalkaloiden has the advantage that possible toxic properties of the extract are significantly reduced.
  • extracts, tinctures and / or extracts of fresh or dried ones Comfrey plants or parts of plants in the range of> 0.01 ppm to ⁇ 10 ppm
  • Pyrrolizidine alkaloids preferably in the range of> 0.05 ppm to ⁇ 1 ppm Pyrrolizidinalkaloide, preferably in the range of> 0.1 ppm to ⁇ 0.5 ppm Pyrrolizidinalkaloide. It is advantageous if the extract of comfrey has ⁇ 1 ppm, preferably ⁇ 0.5 ppm, preferably ⁇ 0.1 ppm, more preferably ⁇ 0.01 ppm Pyrrolizidinalkaloide. In particular, it is advantageous if the comfrey extract in the range of> 0.01 ppm to ⁇ 0.1 ppm Pyrrolizidinalkaloide. Most preferably, the content of Pyrrolizidinalkaloiden is below the detectability limit.
  • the preparation comprises as active ingredients in the range of> 10% to ⁇ 30%, based on the total content of the preparation, preferably 15% extracts, tinctures, essential oils and / or extracts of fresh or dried plants or plant parts of arnica or their dry residue.
  • the preparation comprises as active ingredients in the range of> 2 vol .-% to ⁇ 40 vol .-%, based on the total volume of the preparation, preferably in the range of> 10 vol .-% to ⁇ 30 vol .-%, preferably 15% by volume, liquid extract of fresh or dried plants or plant parts of arnica.
  • the preparation comprises as active ingredients in the
  • composition comprises as active ingredients in the range of> 1.5 vol .-% to ⁇ 40 vol .-%, based on the
  • Total volume of the preparation preferably in the range from> 10% by volume to ⁇ 30% by volume, preferably 15% by volume, of liquid extract of fresh or dried plants or comfrey plant parts.
  • the preparation preferably comprises as active ingredients in the range from> 0.5% by volume to ⁇ 20% by volume, based on the total volume of the preparation, preferably in the range of> 1% by volume. to ⁇ 10% by volume, preferably 5% by volume, of essential oil of fresh or dried plants or plant parts of rosemary.
  • the preparation comprises as active ingredients the following extracts, tinctures, essential oils and / or extracts:
  • the preparation comprises as active ingredients the following extracts, tinctures, essential oils and / or extracts:
  • weight contents of the respective components are chosen so that the total weight of the components does not exceed 100% by weight.
  • the preparation comprises as active ingredients the following extracts, tinctures, essential oils and / or extracts:
  • the preparation comprises as active ingredients the following extracts, tinctures, essential oils and / or extracts:
  • liquid extract of fresh or dried plants or comfrey plant parts preferably 15% by volume liquid extract of fresh or dried plants or comfrey plant parts (Symphytum officinale); c. in the range of> 1% by volume to ⁇ 10% by volume, preferably 5% by volume, of essential oil of fresh or dried plants or parts of plants of rosemary (Rosmarinus officinalis),
  • volume contents of the respective components are chosen such that the
  • Total volume of components does not exceed 100% by volume.
  • Treatment of rheumatic pain and acute joint inflammation beneficial.
  • a circulation-enhancing effect can be provided.
  • an acceleration of the cell structure and cell formation can be effected.
  • the preparation is also advantageously useful for use in dislocations, dull traumas, muscle and joint pain. This is especially true in the treatment of
  • Contortions Contortions, blunt trauma, for example sprains, bruises, strains,
  • Extracts, tinctures, essential oils and extracts can be prepared from whole fresh or dried plants, extracts, tinctures, essential oils and extracts from whole plants or parts of plants, for example, from flowers, leaves, stems, roots or seeds of the plants are preferred.
  • extracts, tinctures, essential oils and extracts of arnica (Arnica montana) from the fresh or dried whole plant or leaves, preferably from the dried flowers.
  • extracts, tinctures and extracts of comfrey can be prepared from the fresh or dried herbaceous parts of plants or the leaves, preferably from the fresh or dried subterranean parts, especially the roots. Extracts, tinctures, essential oils and extracts of rosemary (Rosmarinus officinalis) from the fresh or dried above-ground parts, in particular flowers and / or leaves, are preferably preparable.
  • the preparation comprises extracts, tinctures and / or extracts of comfrey root and / or extracts, tinctures, essential oils and / or extracts of amica flowers and of the aerial parts of rosemary.
  • extracts of plants and / or plant parts of arnica (Arnica montana) and comfrey (Symphytum officinale) are present in the form of an aqueous-ethanolic extract. Extracts and tinctures according to pharmacopoeia are preferred by means of ethanol
  • Water mixtures can be produced.
  • an arnica (Arnica montana) essential oil is also usable.
  • the concentration of ethanol of the aqueous-ethanolic extract of arnica (Arnica montana) ranges from 30% to 86% (v / v), especially 70% (v / v).
  • the concentration of ethanol of the aqueous ethanolic extract of comfrey (Symphytum officinale) is 30% to 86% (v / v).
  • a comfrey aqueous extract is usable.
  • the weight ratio of the comfrey plant parts (Symphytum officinale) to the extract is in the range from 1: 1 to 1:10 (m / m).
  • the so-called drug / extract ratio is in the range from 1: 1 to 1:10 (m / m).
  • the drug / extract ratio indicates which starting amount of plant ("drug") for the preparation of a certain amount of extract, in particular a native extract, is used.
  • the preparation comprises alcoholic, aqueous, or
  • the preparation comprises an arnica essential oil (Arnica montana).
  • the preparation comprises dry extracts obtainable from alcoholic, aqueous or aqueous-alcoholic extracts from fresh or dried plants and / or plant parts of arnica (Arnica montana) and comfrey (Symphytum officinale).
  • the preparation comprises an essential oil of fresh or dried plants and / or plant parts of rosemary (Rosmarinus officinalis). Rosemary essential oil is preferably obtainable by steam distillation from the flowering aerial parts.
  • the preparation comprises aqueous-ethanolic extracts or dry extracts from fresh or dried plants and / or plant parts of arnica (Arnica montana) and comfrey (Symphytum officinale) and an essential oil of fresh or dried plants and / or plant parts of rosemary ( Rosmarinus officinalis).
  • the preparation comprises aqueous-ethanolic extracts or dry extracts of fresh or dried plants and / or plant parts of comfrey (Symphytum officinale) and an essential oil of fresh or dried plants and / or plant parts of arnica (Arnica montana) and rosemary ( Rosmarinus officinalis).
  • the preparation according to the invention may contain the active ingredients, in particular extracts,
  • Tinctures, essential oils and / or extracts also in liposomal or liposomal encapsulated form, ie contained in liposomes have.
  • the preparation may comprise extracts, tinctures, essential oils and / or extracts in liposomally encapsulated form.
  • the preparation according to the invention can therefore also be present in a liposomal dosage form.
  • Components in liposomal encapsulated form can more easily overcome the barrier layer of the skin.
  • the preparation may comprise a combination of the active ingredients, in particular extracts, tinctures, essential oils and / or extracts in liposomally encapsulated and free form.
  • the active ingredients in particular extracts, tinctures, essential oils and / or extracts in liposomally encapsulated and free form.
  • an increase in the effectiveness can be achieved thereby.
  • Liposomes can form a two-phase system, with an aqueous phase of one
  • Lipid phase is included.
  • the active ingredients in particular extracts, tinctures, essential oils and / or extracts can thus be enveloped by the lipid phase of the liposomes.
  • the lipid phase preferably comprises phospholipids. Suitable phospholipids are
  • Phosphoglycerides also called glycerophospholipids, and sphingolipids.
  • Suitable phospholipids are in particular selected from the group of those frequently occurring in cell membranes
  • Phosphohpiden comprising phosphatidylcholine, phosphatidylethanolamm, phosphatidylserine and / or sphingomyeline.
  • phospholipids of natural origin for example from soy or egg, in particular phosphatidylcholine, phosphatidylethanolamm, phosphatidylglycerol,
  • Phosphatidylinositol, phosphatidylserine and phosphatidic acid are also useful in, for example, by catalytic hydrogenation in different degrees of hydrogenation chemically modified form.
  • synthetic and semisynthetic phospholipids such as dibiotmitoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myristoyl-phosphatidylserine and / or dioleoyl phosphatidylcholine.
  • Suitable compositions of phospholipids may also be added with a proportion of minor amounts of other lipids or lipid classes such as neutral lipids, glycolipids and / or sphingomyelins.
  • Suitable liposomes can be prepared in particular from glycerophospholipids, cholesterol and stearylamine and at least one lipid derivative.
  • amphiphilic compounds such as alkylcarboxylic acids can also be used as membrane-forming substances.
  • Other lipids in which the extracts, tinctures, essential oils and / or extract extract may dissolve include olive oil, corn oil and soybean oil.
  • the preparation according to the invention may be in the form of an ointment, cream, gel or lotion.
  • the term “ointment” is understood to mean a single-phase or multiphasic, semi-solid dosage form for use on the skin or mucous membranes, depending on their water content, hydrophobic ointments, water-absorbing ointments and hydrophilic ointments.
  • Pharmaceutically creams and gels are to be distinguished from it.
  • cream is understood to mean a multiphase, semisolid preparation of a hydrophilic and a lipophilic component.
  • the term “gel” is understood to mean a liquid gelled with the aid of swelling substances.
  • the preparation comprises liquid-form extracts, tinctures and / or extracts or their dry residue, in particular arnica and / or comfrey.
  • gels especially hydrogels, can absorb much more liquid extracts than ointments without segregating the phases. Ointments therefore preferably contain the dry residue obtainable from the liquid extracts, tinctures and / or extracts.
  • the preparation therefore comprises extracts of fresh or dried plants and / or plant parts of arnica (Arnica montana) and / or comfrey (Symphytum officinale) in the form of dry extracts.
  • the preparation comprises an essential oil of fresh or dried plants and / or plant parts of arnica (Arnica montana) and / or rosemary (Rosmarinus officinalis) or their dry residue.
  • the preparation is present as an ointment, in particular in the form of a hydrophilic ointment, particularly preferably in the form of a hydrous hydrophilic ointment.
  • Creams are also to be used with advantage in the context of the present invention.
  • a hydrous hydrophilic ointment (Unguentum emulsificans aquosum) is a very water-containing, for example, up to 70% water, and thus not so greasy hydrophilic ointment.
  • the preparation is in the form of hydrophilic or amphiphilic creams or hydrophilic gels.
  • cooling ointments are also usable.
  • Hydrophilic gel preparations as well as hydrophilic ointments and hydrophilic creams can have a cooling effect.
  • this can enhance the positive, in particular the decongestant, effect of the preparation.
  • Creams, preferably hydrophilic creams and / or amphiphilic creams, are also particularly preferred in the context of the present invention.
  • Useful ointment, cream and gel bases are, for example, in the pharmacopoeias
  • German Pharmacopoeia, DAB, or Homeopathic Pharmacopoeia, HAB described. It is preferred according to the invention that the preparation comprises, as ointment, cream or gel base, DAB or DAC components (DAC: Deutscher Arzneiffencodex).
  • Preferred ingredients are, for example, wool wax alcohols, cetylstearyl alcohol, Vaseline, preferably white Vaseline, Cetylpalmitat, waxes, artificial waxes, paraffins, vegetable oils, Sobitanester, polysorbate, glycerol, monoglycerides, Glycerolmonostearat 60, macrogol 1000-glycerol monostearate, Macrogol 20-glycerol monostearate, fatty alcohols , Cetyl alcohol, medium chain triglycerides, propylene glycol and / or cellulose derivatives. According to the invention particularly preferred raw materials are
  • Glycerol monostearate 60 macrogol 1000 glycerol monostearate, macrogol 20 glycerol monostearate, cetyl alcohol, medium chain triglycerides, white vaseline and / or propylene glycol.
  • the preparation comprises as active ingredients the following extracts, tinctures, essential oils and / or extracts: a. in the range of> 2% to ⁇ 40%, calculated on the total content of the preparation, extracts, tinctures, essential oils and / or extracts of fresh or dried plants or parts of plants of arnica (Arnica montana) or their dry residue;
  • the preparation comprises as active ingredients the following extracts, tinctures, essential oils and / or extracts:
  • the preparation has a hydrophilic base after DAC, in particular, hydrophilic ointments and creams on a DAC basis are preferable. It is particularly preferred according to the invention that the preparation comprises as a basis base cream DAC.
  • DAB or DAC ingredients is understood to include ointment, cream or gel bases according to DAB or DAC.
  • the preparation can be based on a base cream DAC already when rubbing into the skin.
  • the formation of a fatty film on the skin is advantageously avoided.
  • the preparation may be completely or almost completely
  • preparations using a base cream DAC can in particular also show a faster onset of action. These are thus very well suited for the treatment of acute swelling in an advantageous manner. A rapid absorption into the skin also allows a repeated application or a more frequent rubbing. This is a big advantage over a slower oily ointment.
  • the preparation has a hydrophilic base after DAB, in particular, a hydroxyethyl cellulose gel DAB is preferable.
  • a Hydroxyethylcellulosegels is that this has a high water content, whereby the
  • Preparation may advantageously also have a cooling effect.
  • hydrophilic gels which have been improved according to the invention
  • the ointment, cream or gel base further comprises substances having a skin-cooling effect, for example menthol.
  • the preparation is in the form of a gel.
  • hydrogels emulsion gels or microgels are preferred.
  • a hydrogel is understood as meaning a water-containing gel.
  • Hydrogels commonly have a high water content and a hydrophilic polymer.
  • Preferred polymers are cellulose-based or polyacrylate-based polymers, for example, cellulose ethers such as
  • Hydroxyethylcellulose gel DAB or polyacrylate derivatives such as carbomers preferably have penetration-promoting additives, for example lecithin derivatives.
  • an emulsion gel is understood to mean an oil-in-hydrogel emulsion in which an oil is distributed in a hydrogel.
  • a lipid component is incorporated into an aqueous-alcoholic gel structure.
  • a combination of cream and gel can combine the positive properties of a cream with those of a gel.
  • an emulsion gel can penetrate quickly and have a pleasant cooling effect.
  • an emulsion gel can remain supple even at low temperatures and can be easily distributed on the skin.
  • this is in the form of a microgel.
  • Microgels are intramolecularly crosslinked macromolecules that may have a colloidal dimension.
  • the ingredients may be contained in micelles. Microgels can advantageously assist in allowing active agents to pass from the gel through the skin barrier.
  • Preferred polymers for microgels are polyacrylic acid copolymers, poly-2-vinylpyridine (P2VP), poly (N-vinylcaprolactam), poly-N-isopropylamide (PNiPAM) or polyamides.
  • Particularly preferred polymers are poloxamer-called block copolymers of ethylene oxide and propylene oxide.
  • microgels contain solubilizers such as dimethyl isosorbide.
  • microgels contain isopropanol.
  • isopropanol improves the permeability of the skin to active ingredients contained in the gel.
  • Embodiments include microgels poloxamer, dimethylisosorbide, isopropanol, and / or medium chain triglycerides.
  • preferred embodiments of the preparation rapidly enter the skin and preferably do not form a greasy film on the skin.
  • Embodiments of the preparation have no side effects. Furthermore, the preparation is advantageously stable and shows no segregation even after prolonged storage. Particularly preferred embodiments of the preparation according to the invention preferably also show no segregation and / or no crystal growth after one year of storage and preferably no or negligible change in appearance, color, odor and / or pH. Furthermore, the preparation may contain other conventional auxiliaries of ointment, cream and / or
  • the pharmaceutical preparation according to the invention preferably also comprises dyes, for example curcumin, curcuma root extract, riboflavin and / or .beta.-carotene. Furthermore, it is preferred that the preparation is ready for use.
  • ready-to-use means that the preparation is present as a ready-to-use ointment, cream or gel which can be applied to the skin.
  • the preparation comprises, based on the
  • the preparation comprises, based on the total content of the preparation:
  • the preparation comprises, based on the total content of the preparation:
  • the preparations preferably have no side effects, advantageously rapidly enter the skin and preferably do not form a greasy film on the skin. Furthermore, the preparations have a very good action against swelling and pain, are stable and show no segregation even after prolonged storage. Surprisingly, it has been found that the preparation according to the invention can advantageously have good efficacy in rheumatic diseases, in particular in the symptomatic treatment of rheumatic pain, or in acute joint inflammation.
  • Preferred embodiments of the preparation according to the invention can advantageously show an improved perfusion-promoting, regenerating and anti-inflammatory action.
  • the preparation according to the invention can contribute to the support of tissue regeneration.
  • the preparation according to the invention can show an analgesic effect. This is particularly advantageous in the symptomatic treatment of rheumatic pain.
  • the preparation according to the invention can also be a good decongestant and
  • analgesic effect is particularly useful in the treatment of dislocations, dull trauma such as sprains, bruises, strains, bruises or bruises, swelling, muscle and joint pain, for example due to blunt injuries, especially in blunt sports injuries or tired legs advantage.
  • Another object of the present invention relates to a preparation according to the invention for use in the treatment of dislocations, dull trauma, for example
  • the treatment may be a therapeutic or prophylactic treatment.
  • the term "prophylactic treatment” is understood in particular to mean that the preparation can be used prophylactically before symptoms occur, for example before swelling occurs.
  • a “prophylactic treatment” is understood as a prevention.
  • a further aspect of the present invention relates to the use of a preparation according to the invention for the preparation of a cosmetic or pharmaceutical agent for the treatment of dislocations, dull traumas, for example sprains, bruises, strains,
  • Bruising or bruising, swelling, muscle and joint pain due to, for example, blunt trauma, symptomatic treatment of rheumatic pain, acute joint inflammation, blunt sports injuries or tired legs.
  • the preparation is applied two to three times a day on the affected skin or joints.
  • the preparation according to the invention is also advantageously suitable for invigorating massage of stressed and tired legs.
  • the preparation according to the invention can also be advantageously used for the long-term treatment of bruises, strains, bruises and bruises as well as broken bones and after operations.
  • the preparation according to the invention is preferably in the form of a rheumatoid and / or sports ointment.
  • Another object of the present invention relates to a rheumatism and / or sports ointment.
  • the rheumatism and / or sports ointment comprises as effective components the following excerpts,
  • Tinctures, essential oils and / or extracts are Tinctures, essential oils and / or extracts:
  • the rheumatism and / or sports ointment preferably comprises the active ingredients together with harmless, especially pharmacologically acceptable ointment, cream or
  • a rheumatism and / or sports ointment comprises in preferred embodiments as active ingredients a preparation of the invention and an ointment, cream or gel base, in particular an ointment base.
  • the rheumatism and / or sports ointment may also be present as a cream or gel.
  • extracts, tinctures and / or extracts of fresh or dried plants and / or plant parts of comfrey (Symphytum officinale) and / or extracts, tinctures, essential oils and / or extracts of arnica (Arnica montana) and rosemary (Rosmarinus officinalis) to the description above.
  • the preparations according to the invention as well as rheumatism and / or sports albums can be prepared by customary processes.
  • the extracts, tinctures, essential oils and / or extracts in ointment, cream or gel bases comprising DAB or DAC ingredients, preferably base cream DAC, a. Extracts, tinctures, essential oils and / or extracts may also be liposomally encapsulated.
  • compositions may comprise an extract, a tincture, an essential oil and / or an extract of a particular plant or its parts.
  • the formulation includes ethanolic extracts of Arnica montana and Symphytum officinale and rosemary essential oil in a gel base of hydroxyethyl cellulose gel.
  • Example 1 The effect of the preparation according to the invention described in the preceding Example 1 was observed in patients with bruises, the gel being applied to the affected joints and skin sites three times a day.
  • Example 1 It was found that the use of the preparation of the invention according to Example 1 a good analgesic and circulation-promoting, regenerating and anti-inflammatory effect could be achieved. Even after repeated application of the gel, no contraindications or side effects were observed.
  • the recipe included dry extract from ethanolic extracts of Arnica montana and
  • Symphytum officinale and rosemary essential oil in an ointment base based on DAC Symphytum officinale and rosemary essential oil in an ointment base based on DAC.
  • the preparation of the invention led in particular in the symptomatic treatment of rheumatic pain to an impressive improvement in symptoms. It could be one in particular compared with known preparations comparable good effect can be achieved, with fewer side effects occurred.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition destinée à une utilisation topique, en particulier dans le cas de maladies rhumatismales, la composition comprenant, comme constituants actifs, des extraits et/ou des teintures de plantes et/ou de parties de plantes fraîches ou séchées de consoude et des extraits, des teintures et/ou des huiles essentielles d'arnica et de romarin.
EP11719233A 2010-05-07 2011-05-06 Composition destinée à une utilisation topique dans le cas de maladies rhumatismales Withdrawn EP2566581A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010019876A DE102010019876A1 (de) 2010-05-07 2010-05-07 Zubereitung zur topischen Verwendung bei rheumatischen Erkrankungen
PCT/EP2011/057302 WO2011138435A1 (fr) 2010-05-07 2011-05-06 Composition destinée à une utilisation topique dans le cas de maladies rhumatismales

Publications (1)

Publication Number Publication Date
EP2566581A1 true EP2566581A1 (fr) 2013-03-13

Family

ID=44119001

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11719233A Withdrawn EP2566581A1 (fr) 2010-05-07 2011-05-06 Composition destinée à une utilisation topique dans le cas de maladies rhumatismales

Country Status (3)

Country Link
EP (1) EP2566581A1 (fr)
DE (1) DE102010019876A1 (fr)
WO (1) WO2011138435A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108532B1 (ro) * 1990-02-26 1994-06-30 Iulia Siminiciuc Produs medicamentos, cu acțiune antireumatismală
IT1252074B (it) * 1991-01-04 1995-05-29 Giuseppe Mastronicola Estratto idroalcolico di erbe e piante medicinali per la cura di: tendiniti-nevriti- sciatalgie-dolori reumatici, articolari, cervicali torcicolli.
WO2006032091A2 (fr) * 2004-09-21 2006-03-30 Lavender Hill Projects Pty Ltd Composition a base d'herbes medicinales
US7923038B2 (en) * 2004-12-01 2011-04-12 Frank Steven R Method and composition for the treatment of muscular-skeletal and related afflictions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011138435A1 *

Also Published As

Publication number Publication date
DE102010019876A1 (de) 2011-11-10
WO2011138435A1 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
DE69629988T2 (de) "Pharmazeutische Grundlage in Salbenform und ihre Verwendung"
EP1073445A1 (fr) Melange de substances pour application topique comprenant du miel et de l'huile d'olive
EP0133151A2 (fr) Onguent pour la peau
WO2011016812A1 (fr) Médicament topique pour le traitement du psoriasis
EP1399173B1 (fr) Preparation pharmaceutique contenant des ingredients actifs extraits de centella asiatica, mahonia aquifolium et viola tricolor
CA2627021A1 (fr) Formulation topique de source naturelle/anesthesiant local/compose ameliorant la penetration utile pour le traitement de la douleur, du prurit et/ou d'une inflammation cutanee
EP2566581A1 (fr) Composition destinée à une utilisation topique dans le cas de maladies rhumatismales
EP0521925B1 (fr) Utilisation du lierre pour le traitement topique du psoriasis
DE102022128474A1 (de) Zusammensetzung umfassend Copaibaextrakt und Magnesiumsalz insbesondere zur Verbesserung des körperlichen Wohlbefindens bei Menstruationsbeschwerden oder bei allgemeinen Verspannungszuständen
EP2120953B1 (fr) Composition pour le traitement topique de maladies cutanées
WO2014184223A1 (fr) Agent et procédé pour le traitement de l'herpès
DE202016106651U1 (de) Entzündungshemmende Komposition aus Cannabidiol und Betulin
DE20320103U1 (de) Pharmazeutische Zubereitung zur topischen Behandlung von Hauterkrankungen
DE202014008066U1 (de) Thymustherapie
RU2266746C2 (ru) Средство для лечения невралгических заболеваний
DE60213522T2 (de) Kombination von Arnica, Ruscus und Menthol
EP3213745B1 (fr) Preparation galenique de nsaid
DE102020110408A1 (de) Kosmetische Formulierung auf Pflanzenbasis
DE202025104092U1 (de) Kosmetische Pflegezusammensetzung mit Manuka-Honig zur Anwendung bei sensibler und zu Hautirritationen neigender Kinder- und Erwachsenenhaut
DE102017002125A1 (de) Kosmetische Zusammensetzung
AT519387B1 (de) Naturheilsalbe
DE102022115137A1 (de) Zusammensetzung mit hepatoprotektiver Wirkung
DE29822501U1 (de) Kosmetisches Gesundheitspflegemittel
CN105287977A (zh) 一种罗勒、芦荟组合物、制剂及其制备方法和应用
DE10126023A1 (de) Zusammensetzung mit therapeutischer Wirksamkeit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130625